IMNM

Rating neutralAI Memo

Immunome

As of 2026-09-19/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-19 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

European varegacestat submission • 2026-12-31

Base target: $27 / p=45% prob

Biggest risk

The valuation remains concentrated around a single late-stage regulatory outcome, with label, launch and commercial uptake unresolved. Earlier-stage programs carry substantial efficacy and safety risk, quarterly R&D expense was $59.9 million, and recent disclosed open-market sales by a director and the chief scientific officer warrant monitoring without proving deterioration in operations. [#PR-EARNINGS-2026-08-11] [#SEC-FORM4-2026-09-15] [#SEC-FORM4-2026-08-12]

Invalidation

Break below $14 or thesis failure.

What would change my mind?

The accepted varegacestat NDA is supported by strong Phase 3 results, while a planned European filing and potential IM-1021 data create additional shots on goal. Cash, equivalents and marketable securities of $520 million at June 30, 2026 were expected to fund operations into 2028, supporting regulatory preparation and pipeline development. [#SEC-8K-2026-08-11]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-19

Base target

$27

p=45%

Bull target

$38

p=30%

Bear target

$14

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Initial IM-1021 lymphoma data
The accepted varegacestat NDA is supported by strong Phase 3 results, while a planned European filing and potential IM-1021 data create additional shots on goal.
Cash, equivalents and marketable securities of $520 million at June 30, 2026 were expected to fund operations into 2028, supporting regulatory preparation and pipeline development.

BearKey bullets

A delayed European submission would reduce confidence in regulatory execution and international expansion.
FDA rejection, delay, restrictive labeling or unexpected post-submission requirements for varegacestat could materially impair the lead-asset valuation.
Initial IM-1021 data could show limited durability, insufficient activity or safety constraints, while IM-1617 and IM-3050 remain first-in-human programs.

WatchKey bullets

European varegacestat submission

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $27 (p=45%)

Target spread vs base: +41% / -48%

Scenario probabilities

Bull Target: $38 (p=30%)Base Target: $27 (p=45%)Bear Target: $14 (p=25%)

Commentary

Primary evidence supports a meaningful regulatory and pipeline milestone stack, but IMNM remains a concentrated, event-driven biotechnology position. The $23.97 anchor is below the supplied $36.31 median target, yet analyst-count, revision, options, short-interest and sufficient social data were unavailable; zero values in those fields denote unavailable packet evidence rather than neutral readings. Because the supplied peers are only size- or stage-based risk benchmarks and the deterministic prior remains negative, this remains a tentative neutral monitoring view rather than a standard-conviction thesis.

As of 2026-09-19 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Initial IM-1021 lymphoma data

Scenarios

Bull Target (Scenario probability)

$38 / p=30% prob

Base Target (Scenario probability)

$27 / p=45% prob

Bear Target (Scenario probability)

$14 / p=25% prob

Analysis 2026-09-19 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
European varegacestat submission
Immunome plans to submit a Marketing Authorization Application for varegacestat in desmoid tumors by year-end 2026. Timely submission would broaden the lead asset's regulatory opportunity, while delay would weaken confidence in execution and launch preparation. [#SEC-8K-2026-08-11]
Prob 75.00% • Move 6.00% • Priced-in 60.00%
EVENT2027-04-28
Varegacestat FDA decision
The FDA accepted the varegacestat NDA for adults with desmoid tumors and set an April 28, 2027 PDUFA target date. Phase 3 RINGSIDE produced an 84% reduction in progression-or-death risk and a 56% confirmed response rate versus 9% for placebo; approval, labeling and commercial readiness remain the central uncertainties. [#SEC-8K-2026-08-11]
Prob 78.00% • Move 30.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Initial IM-1021 lymphoma data
2026-12-31
Management expects initial 2026 data from the ongoing Phase 1 IM-1021 trial, where objective responses have been observed at multiple dose levels. Convincing multi-patient efficacy and safety results could validate a second clinical asset, but early-stage data remain difficult to handicap. [#PR-EARNINGS-2026-08-11]
Prob 65% • Move 18% • Priced-in 35%

Risks

A delayed European submission would reduce confidence in regulatory execution and international expansion.
FDA rejection, delay, restrictive labeling or unexpected post-submission requirements for varegacestat could materially impair the lead-asset valuation.
Initial IM-1021 data could show limited durability, insufficient activity or safety constraints, while IM-1617 and IM-3050 remain first-in-human programs.
R&D spending and simultaneous advancement of several oncology programs could shorten the stated runway if costs rise or development timelines extend.
Recent director and officer open-market sales may weigh on perception, although Form 4 activity alone does not establish a change in operating fundamentals. [#SEC-FORM4-2026-09-15] [#SEC-FORM4-2026-08-12]

Peers

Symbol	Summary
IOVA	Iovance is a similarly capitalized oncology biotechnology company and can frame regulatory, financing and commercialization-transition volatility. Its approved cell-therapy platform and indications differ materially from Immunome's desmoid-tumor and targeted-oncology portfolio, so it is not a direct operating or valuation peer.
IRON	Disc Medicine is a similarly sized clinical-stage biotechnology company useful only for comparing capital intensity and data-driven valuation sensitivity. Its hematology focus provides little direct clinical, regulatory or commercial read-through to Immunome.
NAMS	NewAmsterdam Pharma is a size-matched late-stage biotechnology comparator with lead-asset regulatory concentration. Its cardiovascular focus makes it a milestone-risk benchmark rather than a direct product, indication or commercial peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-19

Loading AI feed…

Symbol

Summary

IOVA

Iovance is a similarly capitalized oncology biotechnology company and can frame regulatory, financing and commercialization-transition volatility. Its approved cell-therapy platform and indications differ materially from Immunome's desmoid-tumor and targeted-oncology portfolio, so it is not a direct operating or valuation peer.

IRON

Disc Medicine is a similarly sized clinical-stage biotechnology company useful only for comparing capital intensity and data-driven valuation sensitivity. Its hematology focus provides little direct clinical, regulatory or commercial read-through to Immunome.

NAMS

NewAmsterdam Pharma is a size-matched late-stage biotechnology comparator with lead-asset regulatory concentration. Its cardiovascular focus makes it a milestone-risk benchmark rather than a direct product, indication or commercial peer.